New basic science research shows what happens when you inhibit JMJD3 through both genetics and pharmacology.

Thousands of samples from patients with coronavirus infections, stored at -112F, hold potential to unlock important secrets.

Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.

Researchers report the ability to improve safety and efficacy using a CRISPR-Cas9 variant known as miCas9.

Researchers report first clinically actionable findings for a rare blood vessel disease in a study of four unrelated families, all with the same genetic variant.

Researchers look to the genes behind COVID-19 for early answers.